|Bid||1.3500 x 1300|
|Ask||1.3500 x 800|
|Day's Range||1.3400 - 1.3900|
|52 Week Range||1.3400 - 7.4800|
|Beta (5Y Monthly)||2.10|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 10, 2022 - Nov 14, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for CGEN
Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that the European Patent Office has granted Compugen a new patent covering anti-PVRIG antibodies for use in cancer treatment.
Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, provided a corporate update and announced financial results for the second quarter ended June 30, 2022.
In this article, we discuss the 7 stocks that Cathie Wood dumped in July. If you want to see more stocks that she disposed of during this month, click Cathie Wood Dumped These 3 Stocks in July. In June, Cathie Wood’s ARK Investment Management suffered a sharp decline in assets, which was decidedly higher than […]